Calo Corinne A, Levine Monica D, Brown Morgan D, O'Malley David M, Backes Floor J
Division of Gynecologic Oncology, The Ohio State University, Columbus, OH, United States.
Department of Obstetrics and Gynecology, The Ohio State University, Columbus, OH, United States.
Gynecol Oncol Rep. 2023 Mar 31;46:101171. doi: 10.1016/j.gore.2023.101171. eCollection 2023 Apr.
Effective second-line treatment options for patients with recurrent ovarian clear cell carcinoma (OCCC) are limited. This case series sought to report tumor characteristics and oncologic outcomes in a small group of patients treated with combination lenvatinib and pembrolizumab. A retrospective analysis of patients with ovarian clear cell carcinoma treated with combination lenvatinib and pembrolizumab at a single institution was performed. Patient and tumor characteristics were collected including demographics and germline/somatic testing. Clinical outcomes were also evaluated and reported. Three patients with recurrent OCCC were included in the study. The median age of patients was 48 years old. All patients had platinum-resistant disease and had received 1-3 prior lines of therapy. The overall response rate was 100% (3/3). Progression-free survival ranged from 10 months to not-yet-reached. One patient remains on treatment, while the other two died of disease with overall survival of 14 and 27 months. Combination lenvatinib-pembrolizumab demonstrated favorable clinical response in these patients with platinum-resistant, recurrent, ovarian clear cell carcinoma.
复发性卵巢透明细胞癌（OCCC）患者有效的二线治疗方案有限。本病例系列旨在报告一小群接受乐伐替尼和派姆单抗联合治疗的患者的肿瘤特征和肿瘤学结局。对在单一机构接受乐伐替尼和派姆单抗联合治疗的卵巢透明细胞癌患者进行了回顾性分析。收集了患者和肿瘤特征，包括人口统计学资料以及种系/体细胞检测结果。还对临床结局进行了评估和报告。该研究纳入了3例复发性OCCC患者。患者的中位年龄为48岁。所有患者均患有铂耐药疾病，且之前接受过1-3线治疗。总体缓解率为100%（3/3）。无进展生存期为10个月至尚未达到。1例患者仍在接受治疗，而另外2例死于疾病，总生存期分别为14个月和27个月。乐伐替尼与派姆单抗联合治疗在这些铂耐药、复发性卵巢透明细胞癌患者中显示出良好的临床反应。
